Money goes where it's treated best. That simple truth is a big reason why more and more money—trillions, in fact—flows into a powerful, low-cost tool that's quietly transformed investing in recent years. Exchange-traded funds, or ETFs, let you invest in everything from the stock market to gold like never before. This biweekly podcast will demystify them—and delight you in the process.
Whoa, That ETF Got Big
Much like kids, ETFs can grow up so fast. And while you can expect the Vanguards and BlackRocks to keep hoovering up assets, there are many lesser-known products that have gained respectable followings. Sometimes it's quite shocking to see just how big they've gotten since the last time you checked on them.
On this episode of Trillions, Eric and Joel are joined by Todd Rosenbluth, Director of Mutual & Exchange Traded Fund Research at CFA, Claire Ballentine, reporter for Bloomberg News and Athanasios Psarofagis, analyst for Bloomberg Intelligence. They discuss and debate eight ETFs that got surprisingly large, including: $XSOE, $IQLT, $IVOL, $SOXL, $BUZZ, $UFO, $TMFC and $BUG.
The REIT Stuff
Let's be honest, Real Estate Investment Trust (REIT) ETFs probably aren't going to make you blush or quicken your pulse. But they can be extremely practical in a portfolio. Typically known for their ability to generate income, this category of ETFs has seen rapid evolution of late with new entrants that focus on areas such as data centers. It's also made picking the right REIT ETF all the more confusing since there's now dozens of them.
On this episode of Trillions, Eric and Joel are joined by REIT trader David Auerbach of World Equity Group as well as Kevin Kelly, a managing partner of Benchmark Investments, the index provider for a few of the new REIT entrants. They discuss the basics of REITs, the pros and cons of category king $VNQ as well as the new generation of REIT ETFs such as $SRVR, $HOMZ, $NETL and, what else, $REIT.
A few decades ago, nobody really questioned vaccines. They were viewed as a standard part of staying healthy and safe. Today, the number of people questioning vaccines risks prolonging a pandemic that has already killed hundreds of thousands of Americans. How we got to this moment didn’t start with the rollout of vaccines or in March 2020, or even with the election of Donald Trump. Our confidence in vaccines, often isn't even about vaccines. It’s about trust. And that trust has been eroding for a long time. Doubt, a new series from Bloomberg’s Prognosis podcast, looks at the forces that have been breaking down that trust. We'll trace the rise of vaccine skepticism in America to show how we got here — and where we’re going. Doubt launches on March 23. Subscribe to Prognosis today on Apple Podcasts, Spotify or wherever you get your podcasts.
Coming Soon: The Pay Check Season 3
More than 150 years after the end of slavery in the U.S., the net worth of a typical white family is nearly six times greater than that of the average Black family. Season 3 of The Pay Check digs into into how we got to where we are today and what can be done to narrow the yawning racial wealth gap in the U.S.
Jackie Simmons and Rebecca Greenfield co-host the season, which kicks off with a personal story about land Jackie's family acquired some time after slavery that they're on the verge of losing. From there the series explores all the ways the wealth gaps manifests and the radical solutions, like affirmative action, quotas, and reparations, that can potentially lead to greater equality.
How to Think About Inflation (and Other Stuff) With Jim Bianco
This month showed how much inflation concerns and an uptick in bond yields can mess with a portfolio. It showed the vulnerability of high flying investments such as bitcoin and ARK as well as how a 60/40 portfolio can have both the 60 and the 40 go down together. So yeah, inflation is a big deal. But is it real or just another head fake?
On this week's episode of Trillions we speak with Jim Bianco, president and founder of Bianco Research LLC, on why he's taking inflation more seriously this time and what a 60/40 investor can do. He also talks ARK ETFs and its haters, bitcoin's potential and why the retail day trader is here to stay even post-pandemic.
ETFs Get Trippy in the Shroom Sector
Magic mushrooms, LSD and ketamine used to be associated with psychedelic trips and fun weekends. Now they’re increasingly viewed as serious medicine that can be used to treat ailments such as depression and PTSD. The small but fast-growing industry even has its first ETF — the Canadian-listed Horizons Psychedelic Stock ETF, or PSYK.
On this episode of Trillions, Eric and Joel speak with Steve Hawkins, the CEO of the firm behind the ETF, who was also behind the world’s first cannabis ETF. He talks the about sector outlook, underlying business fundamentals, the design of the ETF — and whether he plans to start micro-dosing LSD.